37 results about "Dimethyl-L-arginine" patented technology

Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and / or diseases.

The present invention provides methods of detecting asymmetric dimethylarginine (ADMA) in a sample, particularly a sample that may contain symmetrical dimethylarginine (SDMA) and / or arginine. The methods generally involve modifying any SDMA and arginine in the sample such that SDMA and arginine are readily distinguishable from ADMA; and detecting ADMA. The invention further provides antibodies specific for ADMA; antibodies specific for modified SDMA; and antibodies specific for modified arginine. The invention further provides kits for practicing the subject methods.

Provided is a method for using low molecular weight compounds found in the body as a biomarker for diagnosing depression. Specifically, more than one compound selected from a group comprising the following are used: ADP-ribose, ATP, ADP, AMP, serotonin, tryptophan, kynurenine, SDMA (symmetrical dimethylarginine), threonine, glyceric acid, serine, N-acetylaspartic acid, glutamic acid, trigonelline, creatine, 2-methylserine, sphingosine, homovanillic acid, piperidine, sulfoxidized methionine, pipecolic acid, sphinganine, gamma-butyrobetaine, guanidinoacetic acid, isobutyric acid, creatinine, sarcosine, 3-methylbutyric acid, nicotinamide, betaine, ornithine, carnitine, ethanolamine, phosphoethanolamine, taurine, hypotaurine, aspartic acid, methionine, and tyrosine.

The invention belongs to the technical field of immunotherapy. Firstly, dimethylarginine is found to effectively inhibit in-vitro proliferation of T and B cells, so a mechanism of ADMA and SDMA for inhibiting T and B cell proliferation in vivo is studied, and it is found that the ADMA and SDMA induced mitochondrial ROS generation is realized by activating AGXT2 enzyme, and the ADMA and SDMA are converted into a new substance DMGV through the AGXT2 enzyme, thereby the ADMA, the SDMA and the DMGV can effectively inhibit the proliferation of T and B cells; and the ADMA is converted into L-citrulline by dimethylamine hydrolase (DDAH), so the amount of ADMA that enters mitochondria, is converted into DMGV and functions is reduced, and a specific DDAH inhibitor PD404182 is the same as ADMA to suppress T cell proliferation. Therefore, the dimethylarginine, the derivatives thereof and the substances for specifically inhibiting degradation of the dimethylarginine are expected to provide a new direction for treating T and B cell mediated diseases by inhibiting abnormal proliferation of T and B cells.

The invention relates to a method for measuring the concentration of asymmetric dimethylarginine and a diagnostic reagent kit. The method comprises the following steps of: degrading asymmetric dimethylarginine (ADMA) by adopting dimethylarginine dimethylamino hydrolase to generate dimethylamine and citrulline; reacting the citrulline with adenosine triphosphate (ATP) and aspartate under the action of arginine succinate synthetase to generate adenosine monophosphate (AMP); generating inosine monophosphate (IMP) and ammonia by the AMP under the action of AMP deaminase; generating oxidization nicotinamide adenine dinucleotide (NAD) by the ammonia and deamination NAD under the action of NAD synzyme; and calculating the concentration of the ADMA by detecting the concentration of the NAD. The method and the reagent kit are accurate in results, and high in speed, repeatability and interference resistance, and are convenient to popularize and use.

The invention relates to a zymologic method for circularly testing the activity of dimethyl arginine dimethylamine hydrolytic enzyme, and a diagnostic reagent thereof. In a designed product detection method, hydrolysis of asymmetric dimethyl arginine is catalyzed by dimethyl arginine dimethylamine hydrolytic enzyme in a tissue sample to generate citrulline; in a novel design method, citrulline is made to continuously react with an enzyme circular reaction system consisting of citrulline hydrolytic enzyme (EC 3.5.1.20), ornithine carbamoyltransferase (EC 2.1.3.3) and a substrate of the ornithine carbamoyltransferase, so that the reaction sensitivity is greatly enhanced, and the yield of the citrulline is proportional to the activity of the dimethyl arginine dimethylamine hydrolytic enzyme in the sample; and the aim of testing the activity of the dimethyl arginine dimethylamine hydrolytic enzyme in the sample can be fulfilled by testing the generating rate of ammonia in the circular enzyme reaction system. A reagent can be a dry powder reagent, a liquid reagent, a single-dose reagent, a double-dose agent or a multi-dose agent.

The invention discloses a measuring method of asymmetric dimethylarginine concentration, comprising the steps of: subjecting a sample to be measured to a reaction in an enzymatic cycling reaction system, measuring and calculating the generation rate of ammonia from the enzymatic cycling reaction, thus obtaining the content of asymmetric dimethylarginine in the sample to be measured. The enzymatic cycling reaction system consists of dimethylarginine dimethylaminohydrolase, citrullinase, ornithine carbamoyltransferase, and carbamyl phosphate or its salt. The invention also discloses a measuring reagent corresponding to the method. In the invention, an enzymology measuring method and a measuring reagent of asymmetric dimethylarginine are established for the first time. Needing no special instrument, the method of the invention has simple operation, high sensitivity and low cost, thus being able to realize rapid and high flow sample detection in clinic. Thus, asymmetric dimethylarginine is probable to become a conventional inspection item in clinic. Therefore, the method provided in the invention is of great scientific and economic value.

The disclosure is directed to methods and apparatus for the determination, diagnosis, progression and prognosis of kidney disease and mortality associated with kidney disease. The disclosure includes methods for determining renal function, in particular estimating glomerular filtration rate (GFR), in an animal. GFR can be useful in the diagnosis and treatment of kidney disease or dysfunction. In various aspects, the disclosure is directed to the use of free symmetrical dimethylarginine (SDMA) and creatinine in blood samples from animals, in particular cats and dogs, to determine glomerular filtration rate and kidney disease.